{"id":"NCT01277523","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2011-01-17","resultsPosted":"2014-10-20","lastUpdate":"2014-10-20"},"enrollment":392,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"tiotropium high dose","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tiotropium low dose","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"EXPERIMENTAL"},{"label":"C","type":"PLACEBO_COMPARATOR"}],"summary":"The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma.\n\nThe primary objective of the trial is to demonstrate superiority of tiotropium (5 mcg and possibly 2.5 mcg once daily in the evening) over placebo with regard to the primary pulmonary function endpoint after 12 weeks of treatment.\n\nSecondary objectives are to evaluate efficacy of tiotropium with regard to other endpoints, and to evaluate the safety of tiotropium, compared to placebo, as add-on controller therapy on top of usual care in this patient population.","primaryOutcome":{"measure":"FEV1 peak0-3 Change From Baseline","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Placebo Respimat","deltaMin":0.438,"sd":0.045},{"arm":"Tio R2.5","deltaMin":0.55,"sd":0.046},{"arm":"Tio R5","deltaMin":0.528,"sd":0.045}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0457"},{"comp":"OG000 vs OG002","p":"0.1039"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":69,"countries":["United States","Argentina","Australia","Bulgaria","Germany","Guatemala","Hungary","Israel","Latvia","Mexico","Philippines","Portugal","South Africa","Ukraine"]},"refs":{"pmids":["36472162","31319851","27811070"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":135},"commonTop":["Asthma","Peak expiratory flow rate decreased"]}}